Evidence map›Paper›PMID 29699587›Full record

ArticleBMC health services research2018

The association between insurance coverage for insulin pen needles and healthcare resource utilization among insulin-dependent patients with diabetes in China.

Linong Ji, Arthi Chandran, Timothy J Inocencio, Zilin Sun, Qifu Li, Guijun Qin, Zheng Wei, Stefan DiMario, Richard H Chapman

Abstract read
In one paragraph

Article in BMC health services research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Pen Needle Reuse in People with Diabetes Who Inject Insulin: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linong JiEndocrinology, Peking University People's Hospital, Beijing, China.
Arthi ChandranHealth Economics and Outcomes Research, BD, 1 Becton Drive #J315b, Franklin Lakes, NJ, 07417, USA. Arthi.Chandran@bd.com.ORCID 0000-0002-5291-2103
Timothy J InocencioAvalere Health, Washington, DC, USA.
Zilin SunEndocrinology, Southeast University Zhongda Hospital, Nanjing, China.
Qifu LiEndocrinology, Chongqing MU Affiliated No. 1 Hospital, Chongqing, China.
Guijun QinEndocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zheng WeiMedical Affairs, BD and Company, Beijing, China.
Stefan DiMarioBD, Lakes, Franklin, NJ, USA.
Richard H ChapmanAvalere Health, Washington, DC, USA.

Funding

Becton Dickinson and Company n/a
6 · The paper itself

Abstract

backgroundPen needles are an important component of insulin delivery among patients with diabetes, but are not universally covered in China. We compared clinical and economic characteristics of insulin-dependent patients in China who have some level of pen needle (PN) reimbursement to those with no PN reimbursement.

methodsA cross-sectional study was conducted among 400 insulin users with Type 1 or Type 2 diabetes treated in outpatient endocrinology units of four large tertiary care hospitals in Nanjing, Chongqing, Beijing and Zhengzhou. Demographics, medical history, healthcare resource utilization (RU), out-of-pocket costs, insurance and PN reimbursement status were surveyed. Unit costs were assigned to healthcare RU and compared using descriptive statistics and multivariate regression models.

resultsA total of 400 patients were analyzed; 142 (35.5%) with some level of PN coverage/reimbursement and 258 (64.5%) without. Patients without PN reimbursement had a higher prevalence of lipohypertrophy (59.3% vs. 40.7%, p = 0.0007), greater median PN reuse (12 vs. 7 times per needle, p < 0.0001), greater 6-month insulin costs (1591 vs. 1328 Renminbi [RMB], p = 0.0025) and total unadjusted 6-month expenditures (6433 vs. 4432 RMB, p < 0.0001), respectively. After controlling for clinical and demographic characteristics, patients without PN reimbursement had 4.6 times greater odds of high costs compared to those with PN reimbursement.

conclusionsInsulin users without PN reimbursement may pose a greater economic burden to China compared to those with PN reimbursement. Expansion of insurance coverage for insulin PNs can improve the quality of care and potentially help reduce the economic burden in this population.

Indexed as

ChinaCross-Sectional StudiesDiabetes Mellitus, Type 2Drug Delivery SystemsFamily CharacteristicsFemaleHealth ExpendituresHumansHypoglycemic AgentsInjections, SubcutaneousInsulinInsurance CoverageInsurance, HealthMaleMiddle AgedNeedlesHypoglycemic AgentsInsulinChinaCostsDiabetes mellitusInsulinLipohypertrophy

Identifiers

PMID29699587
PMCPMC5921994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.